is compounded semaglutide being discontinued 🚨 FDA Moves to Permanently Shut Down GLP-1s The FDA taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these Patients Cut Off From Cheaper

As a result, the substance remains orally bioavailable without the need for an absorption enhancer

Advertisement Large retrospective analysis may prompt prospective studies How to talk about lifetime risk, treatment goals, Lp(a) testing, statin skepticism and more Robust signal from observational study raises prospect of a long-sought medical therapy Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists Observational evidence of neuroprotection with GLP-1 receptor agonists and SGLT-2 inhibitors Study is first to show reduction in autoimmune disease with the common diabetes and obesity drugs Surgical intervention linked to increased lifespan and reduced complications

Adverse reactions observed during Week 26 to 52 of the Phase 3 clinical trials which had an incidence of 1% and were seen more frequently with tesamorelin relative to placebo are presented in Table 2: For patients who continued from Week 26-52, mean levels of fasting blood glucose, fasting insulin, and HbA1c were not different between the T-T and T-P groups

HPO, hypothalamicpituitaryovarian axis